![Erasca Inc](/common/images/company/N_ERAS.png)
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.03 | 0.96463022508 | 3.11 | 3.3251 | 2.94 | 1949158 | 3.12377758 | CS |
4 | 1.03 | 48.8151658768 | 2.11 | 3.3251 | 2.01 | 3124625 | 2.64101115 | CS |
12 | 1.13 | 56.2189054726 | 2.01 | 3.3251 | 1.81 | 2546572 | 2.44588735 | CS |
26 | 1.39 | 79.4285714286 | 1.75 | 3.3251 | 1.64 | 1576912 | 2.356475 | CS |
52 | 0.51 | 19.391634981 | 2.63 | 3.3251 | 1.51 | 1225212 | 2.2676661 | CS |
156 | -16.66 | -84.1414141414 | 19.8 | 24.47 | 1.51 | 861394 | 5.09084647 | CS |
260 | -12.76 | -80.251572327 | 15.9 | 24.47 | 1.51 | 865304 | 5.23882847 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.